This review discusses emerging evidence supporting the role of testosterone (T), alone or in combination with the aromatase inhibitor anastrozole (T+A), in reducing the incidence of breast cancer and possibly treating existing hormone receptor-positive tumors. Subcutaneous T or T+A implants have demonstrated symptom relief in women with androgen deficiency, including
This 10-year prospective cohort study, known as the Dayton study, evaluated the incidence of invasive breast cancer (IBC) in 1,267 pre- and postmenopausal women treated with subcutaneous testosterone (T) implants, with or without the aromatase inhibitor anastrozole (T+A), for hormone deficiency symptoms. Over 5,667 person-years of follow-up, 11 cases of
This prospective, observational study evaluated breast cancer incidence in 1,268 women treated with subcutaneous testosterone (T) implants, either alone or in combination with the aromatase inhibitor anastrozole (T+A), over a 5-year interim period of a 10-year study. Participants received T or T+A for hormone deficiency symptoms. With a cumulative follow-up
This 2011 prospective cohort study assessed the impact of combined estradiol and testosterone implants on bone mineral density (BMD) in postmenopausal women. Sixty-one participants were divided into two groups: 34 women received hormone implants, while 27 did not undergo hormonal therapy. Over one year, the implant group maintained or slightly
